Introduction
Worldwide, colorectal cancer (CRC) is the third most common cancer, with an estimated 1 233 700 newly diagnosed cases and 608 700 deaths/year in 2008. For this type, Central Europe has repeatedly recorded the highest mortality rates (1) .
Although inherited susceptibility underlies roughly 35% of variance in CRC risk (2) , germ line mutations in genes with high penetrance account for ,6% of cases (3) . There is growing evidence that lifestyle and environmental factors contribute to the CRC development (4) .
Systemic chemotherapy is an important component of the complex treatment of CRC, with regimens based on 5-fluorouracil (5-FU), irinotecan and/or oxaliplatin used as standard. These drugs are often used in combination with biological therapy in patients with advanced disease. Generally, the use of chemotherapy to treat cancers is limited by the inter-individual variability in drug response and the development of cancer cell resistance. Xenobiotics, including anticancer drugs, are extensively metabolised in the body by Phase I (activation enzymes, e.g. cytochromes P450) and Phase II (conjugation enzymes as glutathione S-transferases, GSTs, or glucuronide transferases, UGTs) enzymes. Phase III of biotransformation represented by ATP-binding cassette (ABC) transporters presents another important component of xenobiotic metabolism (5) . ABC transporters play a crucial role in the development of resistance by the efflux of anticancer agents outside of cancer cells (6) . In fact, the expression of ABCs may significantly vary among individuals and thus affects the efficacy of drug treatment (7) .
The human ABC transporters are encoded by a large transporter gene superfamily, which is composed of 49 members grouped into seven subfamilies (A-G) according to the sequence homology. ABC proteins facilitate translocation of heterogeneous substrates including metabolic products, lipids and sterols, peptides and proteins, saccharides, amino acids, inorganic and organic ions, metals and drugs across the cell membrane. To transport these substrates across extracellular and intracellular membranes against a concentration gradient, ABCs use energy acquired by the hydrolysis of ATP (8) . Genetic variation in these genes causes a variety of genetic diseases and disorders (9) . The structure of ABC transporters consists of two types of domains: ATP-binding domains, also known as nucleotide-binding folds (NBFs) and transmembrane domains (TMDs). The NBFs contain typical motifs: Walker A and Walker B and so-called ABC-signature sequence. The TMDs are formed by 6-11 alpha helices and provide the substrate specificity (10) . Although all share a similar NBF, their domains are organised in different ways, with different numbers and localisations of TMDs (11) . Some of the ABCs behave as full transporters with two TMDs, each with six transmembrane segments, and two NBFs. Others are half transporters with only one TMD and become functional after dimerisation or oligomerisation (12) .
The ABCA subfamily contains 12 members acting as full transporters (13; supplementary Table IS, available at Mutagenesis Online). ABCA5 mRNA was detected in poorly differentiated colon adenocarcinoma cell lines G-112 but not in normal colon. In contrast, ABCA2 mRNA was detected in well-differentiated colon adenocarcinoma cell lines CX-1. Thus, induction of ABCA5 may correlate with the differentiation status of human colon tumours and contribute to the tumour development (14) .
The ABCB subfamily consists of 11 members (supplementary Table IIS , available at Mutagenesis Online). Four of them are full transporters (ABCB1, ABCB4, ABCB5 and ABCB11) and the rest is composed of half transporters. P-glycoprotein, a product of ABCB1 gene, is localised in epithelial cells of the small and large intestine as a part of the barrier that protects cells against xenobiotics from diet, bacterial toxins, drugs and other biologically active compounds (15) . ABCB1 confers MDR phenotype to cancer cells (16 (20) . Hypoxia is generally associated with chemoresistance. Ding et al. (21) suggested that hypoxia induced the expression of hypoxia-inducible factor, alpha subunit and ABCB1 in colon carcinoma. Complementary DNA (cDNA) microarray analysis of cell sublines derived from K562 leukaemia, MCF7 breast cancer and S1-colon cancer with acquired resistance against daunorubicin, doxorubicin, vincristine, etoposide and mitoxantrone has shown that ABCB1, ABCB4 and ABCG2 were upregulated in several resistant sublines (22) . ABCB2 and ABCB3 expressions were significantly associated with major histocompatibility complex class I antigen (MHCI) expression in 336 sporadic CRC tumours examined by immunohistochemistry. Thus, the expression of key components of the antigen-processing machinery represented by ABCB2 and ABCB3 is linked with the density of tumour-infiltrating lymphocytes (TILs), which are positive prognostic factors in CRC in vivo (23) .
The ABCC family contains 13 members; nine of them are the multidrug resistance-associated proteins (MRPs; ABCC1,  ABCC2, ABCC3, ABCC4, ABCC5, ABCC6, ABCC10,  ABCC11 and ABCC12, supplementary Table IIIS, available at Mutagenesis Online). In vitro ABCC transporters can collectively confer resistance to anticancer drugs and their conjugated metabolites, platinum compounds, folate antimetabolites, nucleoside and nucleotide analogues (24) . ABCC1 and ABCC2 have been shown to act synergistically with several Phase II enzymes including GSTs and UGTs and this synergy conferred resistance to several drugs (25, 26) . ABCC1 exports drug conjugates with glutathione and unconjugated drugs together with free glutathione (17) . By contrast, ABCC2 transports a wide range of unconjugated organic anions, including e.g. methotrexate, irinotecan or ampicillin (27) . ABCC2 haplotype predicted variability in pharmacokinetics of irinotecan in Japanese metastatic CRC patients treated by FOLFIRI (regimen containing 5-FU and irinotecan) (28) . mRNA expression of ABCC2 was significantly associated with resistance to cisplatin but not 5-FU (29). 5-FU significantly suppressed ATP7B and the organic cation transporter SLC22A2 and increased ABCC2 mRNA expression (5.8-fold) in human cells from colon adenocarcinoma (LS180). Overexpression of ABCC2, ABCC3 and ABCG2 was demonstrated to be beneficial for the efficacy of oxaliplatin in Madin-Darby canine kidney II cells (MDCKII). Thus, the authors predicted that the modulation of expression of transporters of both drugs could favour the synergic action of the FOLFOX (5-FU/leucovorin/oxaliplatin) combination (30) . ABCC5 protein confers resistance to 5-FU by the efflux of monophosphate metabolites. The overexpression of ABCC5 in CRC may contribute to the resistance to 5-FU (31) . In cell lines, celecoxib induced ABCC4 and ABCC5 expression at both mRNA and protein levels, but no induction of ABCC1 and ABCC2 was found. This observation suggested that the low response rate observed in clinical trials using combinations of celecoxib with 5-FU or irinotecan may reflex celecoxib-mediated induction of efflux of drugs from cancer cells through the upregulation of ABCs (32) . Interestingly, patients treated with oxaliplatin-and 5-FU-based regimen for metastatic CRC (n 5 40) had a significantly shorter progression-free survival in the case where their circulating tumour cells (CTCs) expressed alcohol dehydrogenase (ALDH) 1, survivin and ABCC5. Thus, detection of survivinþ/ABCC5þ CTCs from peripheral blood may help in identifying metastatic CRC patients resistant to standard oxaliplatin-and/or 5-FU-based regimen (33) . ABCC11 shares the highest structural similarity with ABCC4 and ABCC5. ABCC11 was also shown to confer resistance to 5-FU and certain fluoropyrimidines (supplementary Table IIIS , available at Mutagenesis Online). The rs17822931 SNP in ABCC11 affects enzyme function that determines earwax type (34) .
The ABCD subfamily consists of four half transporters localised in peroxisomes, providing thus peroxisomal transport of long-chain fatty acids (supplementary Table IVS The six known members of ABCG subfamily are half transporters that have a reversed structure. N-terminus contains NBF and TMD is at the C-terminus (supplementary Table IVS , available at Mutagenesis Online). ABCG2 is a multidrug resistance enzyme that can export both unmodified drugs and drug conjugates, including mitoxantrone, bisantrene, epipodophyllotoxins (e.g. etoposide), camptothecins (topotecan and irinotecan) or flavopiridol (17) . Patients harbouring the À19572 to 19569delCTCA mutation in ABCG2 had a significantly lower relative extent of conversion of irinotecan to its SN-38 metabolite than patients carrying the ancestral genotype without this deletion (P 5 0.019; 36). Dietrich et al. (37) examined 29 colon adenomas from 21 patients and 8 adenomas from C57BL/6 Apc Min/þ mice. ABCG2 protein was significantly down-regulated in both human and mice colon adenomas. ABCG2 confers resistance to a narrower range of anticancer agents than ABCB1 and ABCC1 or ABCC2, e.g. anthracyclines, mitoxantrone and irinotecan. ABCG2 transports the glucuronide conjugate of SN-38, the active metabolite of irinotecan, but with $7-fold lower affinity than unconjugated SN-38 (38) . Dye-efflux effective side population (SP) of SW480 colon cancer cells has shown a higher resistance to 5-FU and irinotecan, higher ABCB1 and ABCG2 expressions and activation of the Wnt signalling pathway when compared to non-SP containing cells. Silencing the Wnt signalling pathway may thus present a promising strategy for targeting chemotherapy-resistant CRC cells (39) . The ABCG5 and ABCG8 form heterodimers and overexpression of putative stem cell marker EpCAM with ABCG5 within the buds of colorectal tumours is frequently observed and associated with poor prognosis (40) .
The current state of knowledge shows that ABCs are functionally important for anticancer drug disposition and efficacy. However, apart from functional data obtained using cell and animal models, there is a limited amount of information on the importance of ABCs for the prognosis of individual patients and the prediction of the chemotherapy outcome. Some of the published studies in patients suggested that ABCs may influence not only cancer initiation but also its progression, invasion and metastasis. The aim of our study is to: (i) explore transcript levels of ABCs in tumour and control tissues from CRC patients treated by substrates of ABCs, (ii) evaluate prognostic potential of ABCs by the correlation of transcript levels with clinical factors such as tumour size, lymphatic node involvement and grading and (iii) elucidate relations between transcript levels of ABCs in tumours and chemotherapy efficacy. In our pilot study presented here, we have addressed these points in a complex way by an assessment of the transcript profile of all known human ABCs. This is because some of the drugs under study are transported by numerous and in some cases unknown transporters. The selection and validation of candidate genetic markers identified in the pilot study are the final goal of our current research.
Materials and methods

Materials
Phenol, chloroform, agarose and chemicals for preparation of buffers were purchased from Sigma-Aldrich (Prague, Czech Republic). Deoxynucleotides (dATP, dCTP, dGTP and dTTP) for polymerase chain reaction (PCR), molecular weight standard for electrophoresis UX174DNA-HaeIII digest and Lambda DNA EcoRI þ HindIII Marker were products of New England Biolabs Inc (Ipswich, MA, USA) and Fermentas Inc (Vilnius, Lithuania), respectively. Taq-Purple DNA polymerase and Combi PPP Master Mix for PCR were supplied by Top-Bio s.r.o. (Prague, Czech Republic).
Subjects
Tissue samples of primary tumour of human colorectal carcinoma and paired distant unaffected mucosa were collected from CRC patients diagnosed and treated at the Departments of Surgery and Oncology, at the Teaching Hospital and Medical School in Pilsen and Charles University in Prague, both in the Czech Republic during the period 2008-10. Native tissue samples were taken during surgery, macrodissected, snap frozen in liquid nitrogen and stored at À80°C until total RNA isolation. The control mucosa samples were taken from the macroscopically unaffected resection margins of colon tissues. The resection margins were microscopically evaluated and only samples free of malignant cells were further analysed. Corresponding tumour tissue samples were verified by the experienced pathologist. Only histologically verified patients and their samples were included in this study. The following data on patients were retrieved from medical records: age, gender, date of diagnosis, pTNM stage according to Union for International Cancer Control (41), histological type and grade of the tumour, type of chemotherapy and treatment response.
The following eligibility criteria were applied to the recruitment of patients into the study: (i) patients who were subject to surgery for CRC, (ii) no prior chemotherapy before surgery (in order to eliminate its influence on transcript levels), (iii) patients who received only first-line chemotherapy in either palliative (Group A) or adjuvant (Group B) setting and (iv) patients who received regimens based on 5-FU, leucovorin and/or oxaliplatin, e.g. FOLFOX.
Response to the treatment was evaluated by Response Evaluation Criteria In Solid Tumors (RECIST) criteria (42) based on routinely used imaging techniques for assessment of tumour mass (by computer tomography, with or without positron emission tomography, magnetic resonance or ultrasonography).
Increase in tumour mass or the appearance of new lesions in patients with palliative treatment (Group A) indicated progression and thus no response to the treatment. Response to the treatment was defined as a decrease of the number or volume of metastases or stabilisation of the disease.
In patients treated by adjuvant therapy after radical surgical resection R0 (Group B), disease-free interval (DFI) served as the treatment outcome for analyses. DFI was defined as the time elapsed between radical surgical R0 resection and disease recurrence. CRC patients treated by 5-FU and/or oxaliplatin were monitored for adverse symptoms of treatment and toxicity was scored according to the National Cancer Institute Common Toxicity Criteria, Version 2, during the whole period of treatment. Grade 3 or 4 toxicity was followed as an important factor of toxicity of the administered regimens.
All patients were informed about the study aims, methods and potential risks and signed consensually an informed consent form in agreement with the requirements of the Ethical Commission of the Medical Faculty and Teaching Hospital in Pilsen, Czech Republic.
Isolation of total RNA and cDNA preparation Methods were published (19, 43) and are presented in the supplementary Material, available at Mutagenesis Online.
Quantitative real-time PCR The diluted amplified cDNA was used for quantitative real-time polymerase chain reaction (qRTPCR) by the relative standard curve method performed in 7500 and ViiA7 Real-Time PCR System using TaqMan Gene Expression Assays (Life Technologies). The following criteria were applied to the selection of TaqMan Gene Expression Assays: (i) exon-exon boundaries span where possible, in order to minimise signals from traces of contaminating DNA, (ii) as short as possible amplicons and (iii) location near to 3#-end of the transcript to reduce possible influence of RNA quality on qRTPCR. The list of reference genes, genes of interest and respective assays is given in supplementary Table VIS, available at Mutagenesis Online. Cycling parameters of qRTPCR were initial hold at 50°C for 2 min and initial denaturation at 95°C for 10 min, followed by 50 cycles consisting of denaturation at 95°C for 15 sec and annealing at 60°C for 60 sec (except ABCC9, ABCG4 and ABCG5 where 90 sec and ABCB1 where 58°C for 90 sec were used). Each reaction contained 2.5 ll of 20 times diluted preamplified cDNA, 5 ll of TaqMan Gene Expression Master Mix and 0.5 ll of TaqMan Gene Expression Assay in a final reaction volume of 10 ll. Fluorescence was acquired after each extension step. Each sample was assessed in duplicate and the mean value was used for further analyses. Samples with .15% variation between duplicates were reanalysed. The non-template control contained water instead of cDNA. Negative cDNA synthesis controls (RNA transcribed without reverse transcriptase) were also employed to reveal possible carry-over contamination. One sample of normal colon mucosa was used as calibrator for preparation of standard curves for each gene to assess reaction efficiency. For the real-time PCR reactions, preamplified cDNA of the calibrator diluted 1:4 was used as the highest template concentration point for construction of the standard curve. The rest of the standard curve points were prepared by five subsequent serial five times dilutions. The resulting standard curve was used for calculation of PCR efficiency (E) according to the following formula: E 5 10 À1/slope À 1 (supplementary Table VIS 
Statistical analyses
Transcript levels were analysed by 7500 and ViiA7 System Software. Acquired average C T values were further processed by relative expression software tool (REST) 2009 Software (47; Qiagen, Hildesheim, Germany). REST is routinely used for the determination of differences between different types of sample and control groups and considers both normalisation to numerous reference genes and reaction efficiency. For statistical analyses of correlation of transcript levels of all established genes with clinical data, the non-parametric tests as MannWhitney, Kruskall-Wallis and Spearman rank tests were used according to the distribution of data. The mean, median, SD, variance, minimum, maximum, quantiles, frequencies and other basic statistical measurements were computed in the given groups and subgroups. The relations between the parameters were computed by Spearman correlation coefficient. The DFI analyses were performed by Kaplan-Meier Survival estimates and Cox regression hazard model. In the first step, each of the investigated covariates were divided into four groups using quartiles of the investigated variable. For these groups, the Kaplan-Meier survival functions were computed. All possible cut-offs were tested and the 'optimal cut-off' was defined as the highest statistical significance in Kaplan-Meier (log-rank test). For these cut-offs, the hazard ratios (HRs) were then computed. In order to reduce the chance of Type I and II errors, only the cut-offs, where the DFI divided by quartiles had a similar direction to the DFI, were used. P-values are always departures from two-sided tests. A P-value of ,0.05 was considered statistically significant. Statistical analyses of clinical data were performed using SPSS v15.0 software (SPSS Inc, Chicago, IL, USA).
Results
Fifty-one patients meeting the eligibility criteria were recruited into the study (26 patients in the palliative Group A and 25 patients in the adjuvant Group B). The clinical and pathological characteristics of the patients are listed in Table I . Patients in both groups did not significantly differ in terms of gender, age at diagnosis, tumour size, lymph node involvement and grading. On the other hand, patients significantly differed in metastatic spread of the disease (all patients in the palliative group were M1 versus M0 in all adjuvant patients) and subsequent treatment (the palliative group was treated predominantly by more aggressive FOLFOX regimen). Tumour localisation also significantly differed between both groups (rectum prevailed in the palliative group versus adjuvant group,
Therefore, the importance of transcript levels of ABCs for overall survival was not evaluated. DFI was evaluated as a measure of short-term survival; 72% of censors occurred in the course of follow-up.
Differences in transcript levels of ABCs between tumour and control tissues
A large number of ABC transcripts were down-regulated in tumour versus control mucosa tissues (REST 2009 software, Table II ). Among these, ABCA1, ABCA4, ABCA5, ABCA6, ABCA8, ABCA9, ABCA10, ABCB1, ABCB4, ABCB5, ABCB11, ABCC3, ABCC5, ABCC6, ABCC7, ABCC8, ABCC13, ABCD2, ABCD3, ABCD4, ABCG1 and ABCG2 transcripts were down-regulated at a very high level of significance (P 0.001). Contrastingly, ABCA12, ABCA13, ABCB6, ABCC1, ABCC2 and ABCE1 were up-regulated in tumours versus control tissues to a high extent (Table II) . The remaining ABCs did not show significant deregulation in compared tissues. Transcript level of ABCC12 was below the limit of detection in all samples.
Correlations between transcript levels of ABCs in tissues and clinical data
Relative transcript levels of ABCs were first normalised to six reference genes. Average C T value of EIF2B1, MRPL19, PSMC4, POLR2A, PPIA and HPRT1 transcript levels was calculated for each sample and designated as ENDO value. Twelve patients also received Avastin in combination. Significant differences between groups in bold.
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Then, the ratio of C T values for ABC gene/ENDO was calculated and used for non-parametric tests as described in Materials and methods. Thus, the higher ABC/ENDO ratios signify lower relative ABC transcript levels. Clinical characteristics presented in Table I were correlated with transcript levels of ABC genes in tumour tissues. A significant inverse correlation between ABCC10 and tumour grade was found; the higher the grade, i.e. the more aggressive the tumour, the lower the ABCC10 transcript level (Table III) . Transcript levels of ABCA12, ABCC7 and ABCC8 in tumour tissues had the following significant trend in tumour localisation: colon , rectosigmoideum , rectum. Interestingly, all three of the above listed transcripts followed exactly the same trend in control tissues as in tumours (Table III) . However, ABCB9, ABCB11, ABCG5 and ABCG8 followed the opposite significant trend, i.e. a decrease in transcript levels in the direction from colon to rectum (Table III) .
Relations between transcript levels of ABCs in tumours and chemotherapy outcome
In the group of patients with metastatic CRC, the response to the palliative chemotherapy significantly correlated with the transcript levels of ABCC6, ABCC11, ABCF1 and ABCF2 (Table III ). In the group of patients with radically R0 removed tumours, the DFI after adjuvant chemotherapy was influenced by transcript levels of several ABCs. Patients with a low transcript level of ABCA7 (cut-off ! 1.25) had a significantly shorter DFI (P 5 0.033, log-rank test) and a higher HR of progression than patients with a high transcript level (HR 5 5.09, 95% HR confidence limits 5 0.97-6.7; Figure 1A) . Similarly, patients with low transcript levels of ABCA13 (cutoff ! 1.58), ABCB4 (cut-off ! Figure 1B -E) than patients with high transcript levels. ABCC11 was thus a significant predictor of chemotherapy outcome in both groups of patients.
Discussion
The efflux of endogenous substrates and also xenobiotics including anticancer drugs out of the cells presents the principal activity of ABCs. Thus, ABCs could be important for both CRC onset and CRC treatment outcome. A number of monogenic disorders have been associated with ABCs, e.g. mutations in ABCC7 gene with the onset of cystic fibrosis and thus, the analysis of mutations in ABCs is routinely used for genetic testing (9) . Although some of the studies observed significant associations between polymorphisms in ABCs and the cancer risk, including CRC, there has been no validated marker among all known 49 human ABCs for CRC prognosis and therapy outcome prediction until now. Based on the results of our pilot study, we propose ABC10 and ABCC11 as such markers and targets for validation studies focused on their confirmation or rejection. Despite numerous published studies in animals and cell models showing the functional impact of ABCs on multidrug resistance, no convincing evidence of a clinical utility of ABCs as markers for the prediction of chemotherapy outcome in cancer patients has been published to date. The majority of published studies deal with associations of SNPs with therapy outcome or toxicity. However, there is limited knowledge about the association between genotype and phenotype. The reason may be the complexity of ABCs, which are promiscuous and overlap in spectra of transported substrates. The lack of information about gene and protein expressions and activity of ABCs in homogenous groups of patients treated by the same spectra of drugs further complicates the evaluation of their importance. CRC seems to be a suitable disease for the pharmacogenomic profiling of ABCs because it is routinely treated by prototypical substrate of certain ABCs, 5-FU. Therefore, we have conducted a pilot study aimed at the evaluation of transcript profiles of all human ABCs in two Significantly deregulated genes by REST software (P-value displayed); NS-non significant.
groups of CRC patients strongly differing in prognosis.
Patients who underwent the radical surgical resection of the tumour have better prognosis than patients with the metastatic disease. Both groups were treated by chemotherapy regimens based on 5-FU and the short-term evaluation of response to this treatment was available. We hypothesised that a strong effect of potential marker(s) should be clearly visible in both groups. As far as we are aware, this is the first complex study of the role of ABC transporters in the tumour development and treatment conducted on CRC patients. The majority of the studied ABCs were down-regulated or unchanged between tumours and non-neoplastic control tissues in this study. ABCA12, ABCA13, ABCB6, ABCC1, ABCC2 and ABCE1 were up-regulated in tumours versus control tissues. There are several studies on the assessment of transcript or protein levels of the selected ABCs (usually ABCB1, ABCG2 and members of ABCC subfamily) in the literature of CRC. Our data comply with the previous reports with regard to the down-regulation of ABCB1 (20) and ABCC3 as well as the up-regulation of ABCC2 in colorectal tumours (29) . In addition, we found the up-regulation of ABCC1 that had not been previously detected (29) . Moreover, our results confirmed the previously observed down-regulation of ABCG2. ABCG2 mRNA showed a 6-fold decrease in colorectal tumours in comparison with control tissues (48) . A ubiquitous expression of ABCE1 mRNA in normal and tumour colon tissues was found. Among 21 peptides with the HLA-A2-binding motifs, two ABCE1-derived peptides were recognised by the colon cancer-reactive cytotoxic T lymphocytes in a dose-dependent manner. The authors suggested that ABCE1 and its peptides could be target molecules in specific immunotherapy for HLA-A2-positive CRC patients (49) . Our observation of significant up-regulation of ABCE1 in tumour tissue of CRC patients, if confirmed by independent study, may be relevant for targeted therapy of CRC. There are no literature data on transcript or protein levels of other ABCs in tumour and non-neoplastic tissues from a series of CRC patients.
The analysis of the tumour localisation has identified highly interesting trends. Transcript levels of certain ABCs increased or declined in direction from colon to rectum in a significant trend. Firstly, we noticed this effect in the tumour tissues. To discern this effect from possible deregulation of mRNA expression by the tumour pathophysiology, we analysed the tissue distribution of transcripts of ABCs also in non-neoplastic control tissues. The same ABCs as in tumours, namely ABCA12, ABCC7 and ABCC8, were found differentially distributed in control tissues maintaining the same trend towards localisation (increase from colon to rectum). Additionally, ABCB9, ABCB11, ABCG5 and ABCG8 followed the opposite significant trend, i.e. a decrease in transcript levels in direction from colon to rectum. Significant changes in gene and protein expression along the anterior-posterior intestinal axis were observed for solute carrier transporters in mice (50) . Moreover, mRNA expression levels of murine Abcb2, Abcb3, Abcb9, Abcc3, Abcc6, Abcd1, Abcg5 and Abcg8 displayed significantly differential gene expression along the duodenum, jejunum, ileum and colon (51) . In human samples, the expression of mRNA for ABCB1 and ABCC2 was highest in jejunum and decreased towards more distal regions, whereas ABCC1 was equally distributed in all intestinal regions (52). We did not confirm the results of Gutmann et al. (53) who found that mRNA expression of ABCG2 was maximal in the duodenum and decreased continuously down to the rectum, perhaps due to the fact that we had no access to samples from duodenum. Moreover, human ABCs identified by us to be differentially distributed in colorectal tissues have not been studied in this regard yet. A possible relevance of the observed gradient in expression of ABCs for efficacy of CRC chemotherapy shall be further studied.
The majority of clinically associated ABCs were either down-regulated or unchanged in tumours versus control tissues. In terms of chemotherapy outcome, the induction of mRNA levels of ABCs and subsequent enhancement of their effect cannot be ruled out. In fact, the ABCG2 mRNA content in hepatic metastases was found to be higher after an 
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irinotecan-based chemotherapy than in irinotecan-naïve metastases (54) . However, the access to post-operative liver metastases in the studied group of patients was limited and such analysis will be the subject of the validation study. In this context, it seems quite interesting that, according to recent study, synchronous or metachronous liver metastases could be treated differently on the basis of different gene expression signatures (55) . The transcript level of ABCC10 in tumours correlated with the grade in our study. There are no data on ABCC10 role in CRC in the literature. The lower ABCB1 expression was found in poorly differentiated CRC tumours (P , 0.05; 20) in line with the study on cell lines, where ABCB1 had a higher expression in well-differentiated colon cancer cells, when compared with the poorly differentiated ones (14) . An increasing expression of another member of ABCC subfamily, ABCC3 with higher grade, i.e. the opposite trend to our observation with ABCC10, was found in pancreatic tumours (56) . No further data on the association of other ABCs with grading in CRC are currently available. Zhang et al. (57) indicated that ABCB1 expression significantly correlated with tumour localisation (P 5 0.039) and gender (P 5 0.043). The intensity of immunohistochemical ABCG2 protein staining was higher in tumours of CRC patients with lymph node positive than in negative disease (30 versus 6.7%, respectively; P , 0.025). Thus, it seemed that ABCG2 expression may be important for progression and metastasis of CRC (58) . Our pilot study, however, did not confirm any of the above published associations.
In the group of patients treated by palliative chemotherapy, the response was analysed using RECIST criteria. Patients were divided into two groups (responders versus nonresponders). Transcript levels of ABCC6, ABCC11, ABCF1 and ABCF2 were significantly higher in responders in comparison with non-responders. In the group of patients treated by the adjuvant chemotherapy after the radical surgical resection of tumour, the relation between transcript levels of ABCs and DFI was evaluated. DFI was significantly shorter and HR of progression higher in patients with low transcript levels of ABCA7, ABCA13, ABCB4, ABCC11 and ABCD4, suggesting that these genes play a role in the therapy outcome of patients treated by the adjuvant chemotherapy. Thus, ABCC11 was up-regulated in the chemotherapy-naïve tumours from patients who subsequently achieved a good response to the chemotherapy in both palliative and adjuvant groups. ABCC11 was shown to be a resistance factor for fluoropyrimidines (34). Oguri et al. (59) discovered that expression of the ABCC11 is induced by 5-FU and that ABCC11 is directly involved in 5-FU resistance by the efflux transport of the active metabolite FdUMP in human small-cell lung cancer cell lines. We hypothesise that the high ABCC11 expression in tumours before chemotherapy observed in both groups of CRC patients studied by us may limit further induction of ABCC11 by 5-FU treatment. However, to confirm or reject our idea, we need to analyse post-chemotherapy samples from the same patients or run a larger validation study.
It is also interesting that the most studied ABCs in the area of chemoresistance, ABCB1, ABCC1-5 and ABCG2 did not predict 5-FU therapy outcome in our CRC patients. We cannot add more evidence to the results of the recent study reporting that ABCC1 in CRC tissues could predict the reduced folate level after leucovorin administration and determine the efficacy of treatment by leucovorin (60). Schmidt et al. (61) observed up-regulation of ABCC6 in 5-FU-resistant colon tumour cell lines. Quite recently, ABCC3, ABCC4 and ABCC5 were found up-regulated in 5-FU-resistant pancreatic carcinoma cells (62) . Nevertheless, results obtained using rather uniform cell line models cultured in the presence of a drug for a long time may not reflect the real situation in such a heterogeneous entity as colorectal tumour or a series of such tumours. As regards, observation in cancer patients, a significant deregulation of gene expression in a number of ABCs was found in breast cancer patients (n 5 19) receiving preoperative (neoadjuvant) chemotherapy regimens including 5-FU. ABCA1, ABCA12, ABCB6, ABCC5, ABCC11 and ABCC13 were down-regulated in patients with complete pathological response, in comparison with patients with residual disease. In contrast, ABCB2, ABCC7 and ABCF2 were up-regulated in patients with complete pathological response (63) . In breast cancer patients treated with endocrine therapy, ABCF2 protein immunopositive tumours had a longer disease-free survival when the tumours were oestrogen receptor negative or progesterone receptor negative (P 5 0.002 and 0.005, respectively; 64). Thus, the up-regulation of ABCF2 observed by us in CRC patients corresponds to available data on breast and cervical cancers. It seems obvious that ABCs have tumourspecific expression profiles (65) and thus also different roles in the mechanism of chemoresistance of the cancer cell (summarised in Figure 2) . Thus, further studies are needed to evaluate the importance of the results obtained by this study.
The study of transcript levels rather than protein expression may be seen as the major limitation of our study. The power of protein analysis is obvious. However, the use of immunohistochemical analysis is semi-quantitative and reflects only protein level and not its activity. In addition, the issue of availability, specificity and selectivity of the antibodies further limits protein analysis. The correlations between transcript and protein levels of human ABCs are mostly unknown and thus, we shall consider transcript levels as independent markers. For the assessment of transcript levels, we have used highly sensitive methods based on real-time PCR, which is superior to relative or semi-quantitative approaches. The small sample size and absence of correction for multiple testing could be seen as another limitation of our pilot study. Thus, all results should be interpreted with caution and need to be confirmed by both retrospective and prospective validation studies on a larger and independent series of CRC patients.
In conclusion, our pilot study brings to light new and interesting data. Transcript levels of all known human ABC transporter genes were assessed in a series of tumour and control tissue samples from well-characterised CRC patients. Several genes were found deregulated in tumours compared with control tissues and a gradient of transcript levels along the superior-inferior axis of the large intestine was observed for the first time. The comparison of outcomes of patients treated by the 5-FU-based regimens suggested that ABCC11 may present a promising candidate marker. The validation of candidate genetic markers identified in the pilot study will be the next goal of our current research.
Supplementary data
Supplementary Table IS-VIS and Material are available at Mutagenesis Online. 
